The effect of intradetrusor botulinum neurotoxin type A on urinary NGF, TGF BETA‐1, TIMP‐2 levels in children with neurogenic detrusor overactivity due to myelodysplasia
Aims The aim of this study was to determine the value of urine nerve growth factor (NGF), transforming growth factor beta 1 (TGF‐Beta‐1), tissue inhibitor of matrix metalloproteinase 2 (TIMP‐2) levels to predict the urodynamic profile before and after botulinum neurotoxin type A (BoNT‐A) treatment i...
Gespeichert in:
| Veröffentlicht in: | Neurourology and urodynamics 2017-09, Vol.36 (7), p.1896-1902 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1902 |
|---|---|
| container_issue | 7 |
| container_start_page | 1896 |
| container_title | Neurourology and urodynamics |
| container_volume | 36 |
| creator | Top, Tuncay Sekerci, Cagri Akin Isbilen‐Basok, Banu Tanidir, Yiloren Tinay, Ilker Isman, Ferruh Kemal Akbal, Cem Simsek, Ferruh Tarcan, Tufan |
| description | Aims
The aim of this study was to determine the value of urine nerve growth factor (NGF), transforming growth factor beta 1 (TGF‐Beta‐1), tissue inhibitor of matrix metalloproteinase 2 (TIMP‐2) levels to predict the urodynamic profile before and after botulinum neurotoxin type A (BoNT‐A) treatment in children with myelodysplasia.
Methods
This prospective study included 15 children with myelodysplasia who underwent intradetrusor BoNT‐A injections due to neurogenic detrusor overactivity (NDOA). Urine samples of each child were collected before and after BoNT‐A injections, specifically at the first and third postoperative months. Urine samples were analyzed with ELISA method and NGF, TGF‐Beta‐1, and TIMP‐2 levels were measured. Urine marker levels and clinical findings were assessed for statistical significance with Wilcoxon Signed Ranks Test and Friedman Test.
Results
A total of 15 children (5 boys and 10 girls) were assigned as the study group. Mean age of the patients was 7.1 ± 2.5 years (range 2.5‐11). A statistically significantly decline was observed in urinary TGF‐Beta‐1 and NGF levels following BoNT‐A injections, compared to the preoperative levels (P |
| doi_str_mv | 10.1002/nau.23207 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1931289782</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1931289782</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3207-a146c06c82bca97979b4bf5257ded4645148de7a9d3419041914641fcd0161d23</originalsourceid><addsrcrecordid>eNp1kc9u1DAQhy0EokvhwAsgS5yQSGs7Tpwcl6q7VCqFw_YcOfaEdZW1F__ZkhuPwIvwUjwJXlJ6Q5blGenzN9L8EHpNyRklhJ1bmc5YyYh4gha0YqSohRBP0YKIsiwYr8UJehHCHSGkKXn7HJ2whrSkrtoF-rXZAoZhABWxG7Cx0UsN0afgPO5dTKOxaYctJO-i-24sjtMe8BI7i5M3VvoJ36xX7_FmvcIfLjfL3z9-0txdffqSK4ZHOMAYsherrRm1B4vvTdzOwq9gjcKP49wBvFTRHEycsE6Ao8O7CUanp7AfZTDyJXo2yDHAq4f3FN2uLjcXH4vrz-uri-V1oY5bKCTltSK1alivZCvy6Xk_VKwSGjSveUV5o0HIVpectiTf_IHTQWlCa6pZeYrezt69d98ShNjdueRtHtnRtqSsaUVzpN7NlPIuBA9Dt_dmlzfSUdIdg-lyMN3fYDL75sGY-h3oR_JfEhk4n4F7M8L0f1N3s7ydlX8ARKeagg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1931289782</pqid></control><display><type>article</type><title>The effect of intradetrusor botulinum neurotoxin type A on urinary NGF, TGF BETA‐1, TIMP‐2 levels in children with neurogenic detrusor overactivity due to myelodysplasia</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Top, Tuncay ; Sekerci, Cagri Akin ; Isbilen‐Basok, Banu ; Tanidir, Yiloren ; Tinay, Ilker ; Isman, Ferruh Kemal ; Akbal, Cem ; Simsek, Ferruh ; Tarcan, Tufan</creator><creatorcontrib>Top, Tuncay ; Sekerci, Cagri Akin ; Isbilen‐Basok, Banu ; Tanidir, Yiloren ; Tinay, Ilker ; Isman, Ferruh Kemal ; Akbal, Cem ; Simsek, Ferruh ; Tarcan, Tufan</creatorcontrib><description>Aims
The aim of this study was to determine the value of urine nerve growth factor (NGF), transforming growth factor beta 1 (TGF‐Beta‐1), tissue inhibitor of matrix metalloproteinase 2 (TIMP‐2) levels to predict the urodynamic profile before and after botulinum neurotoxin type A (BoNT‐A) treatment in children with myelodysplasia.
Methods
This prospective study included 15 children with myelodysplasia who underwent intradetrusor BoNT‐A injections due to neurogenic detrusor overactivity (NDOA). Urine samples of each child were collected before and after BoNT‐A injections, specifically at the first and third postoperative months. Urine samples were analyzed with ELISA method and NGF, TGF‐Beta‐1, and TIMP‐2 levels were measured. Urine marker levels and clinical findings were assessed for statistical significance with Wilcoxon Signed Ranks Test and Friedman Test.
Results
A total of 15 children (5 boys and 10 girls) were assigned as the study group. Mean age of the patients was 7.1 ± 2.5 years (range 2.5‐11). A statistically significantly decline was observed in urinary TGF‐Beta‐1 and NGF levels following BoNT‐A injections, compared to the preoperative levels (P < 0.05). TIMP‐2 levels also tend to decrease following BoNT‐A injections but this was not statistically significant compared to the preoperative levels.
Conclusion
This preliminary study, suggests urinary TGF‐Beta‐1 and NGF as a potent marker in children with NDOA, as they decline following BoNT‐A injection. Further studies are needed in identifying their special role in assessing treatment success after invasive interventions.</description><identifier>ISSN: 0733-2467</identifier><identifier>EISSN: 1520-6777</identifier><identifier>DOI: 10.1002/nau.23207</identifier><identifier>PMID: 28090659</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Acetylcholine Release Inhibitors - therapeutic use ; Biomarkers ; botulinum neurotoxin type A ; Botulinum toxin ; Botulinum toxin type A ; Botulinum Toxins, Type A - therapeutic use ; Child ; Child, Preschool ; Children ; Enzyme-linked immunosorbent assay ; Female ; Growth factors ; Humans ; Injections, Intramuscular ; Male ; Matrix metalloproteinase ; Metalloproteinase ; myelodysplasia ; Myelodysplastic syndrome ; Myelodysplastic syndromes ; Nerve growth factor ; Nerve Growth Factor - urine ; Neural Tube Defects - complications ; Prospective Studies ; Statistical analysis ; tissue inhibitor of matrix metalloproteinase 2 ; Tissue inhibitor of metalloproteinase 2 ; Tissue Inhibitor of Metalloproteinase-2 - urine ; transforming growth factor beta 1 ; Transforming Growth Factor beta1 - urine ; Transforming growth factor-b1 ; Treatment Outcome ; Urinary Bladder, Neurogenic - drug therapy ; Urinary Bladder, Neurogenic - etiology ; Urinary Bladder, Neurogenic - urine ; Urinary Bladder, Overactive - drug therapy ; Urinary Bladder, Overactive - etiology ; Urinary Bladder, Overactive - urine ; Urine ; Urodynamics</subject><ispartof>Neurourology and urodynamics, 2017-09, Vol.36 (7), p.1896-1902</ispartof><rights>2017 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3207-a146c06c82bca97979b4bf5257ded4645148de7a9d3419041914641fcd0161d23</citedby><cites>FETCH-LOGICAL-c3207-a146c06c82bca97979b4bf5257ded4645148de7a9d3419041914641fcd0161d23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fnau.23207$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fnau.23207$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28090659$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Top, Tuncay</creatorcontrib><creatorcontrib>Sekerci, Cagri Akin</creatorcontrib><creatorcontrib>Isbilen‐Basok, Banu</creatorcontrib><creatorcontrib>Tanidir, Yiloren</creatorcontrib><creatorcontrib>Tinay, Ilker</creatorcontrib><creatorcontrib>Isman, Ferruh Kemal</creatorcontrib><creatorcontrib>Akbal, Cem</creatorcontrib><creatorcontrib>Simsek, Ferruh</creatorcontrib><creatorcontrib>Tarcan, Tufan</creatorcontrib><title>The effect of intradetrusor botulinum neurotoxin type A on urinary NGF, TGF BETA‐1, TIMP‐2 levels in children with neurogenic detrusor overactivity due to myelodysplasia</title><title>Neurourology and urodynamics</title><addtitle>Neurourol Urodyn</addtitle><description>Aims
The aim of this study was to determine the value of urine nerve growth factor (NGF), transforming growth factor beta 1 (TGF‐Beta‐1), tissue inhibitor of matrix metalloproteinase 2 (TIMP‐2) levels to predict the urodynamic profile before and after botulinum neurotoxin type A (BoNT‐A) treatment in children with myelodysplasia.
Methods
This prospective study included 15 children with myelodysplasia who underwent intradetrusor BoNT‐A injections due to neurogenic detrusor overactivity (NDOA). Urine samples of each child were collected before and after BoNT‐A injections, specifically at the first and third postoperative months. Urine samples were analyzed with ELISA method and NGF, TGF‐Beta‐1, and TIMP‐2 levels were measured. Urine marker levels and clinical findings were assessed for statistical significance with Wilcoxon Signed Ranks Test and Friedman Test.
Results
A total of 15 children (5 boys and 10 girls) were assigned as the study group. Mean age of the patients was 7.1 ± 2.5 years (range 2.5‐11). A statistically significantly decline was observed in urinary TGF‐Beta‐1 and NGF levels following BoNT‐A injections, compared to the preoperative levels (P < 0.05). TIMP‐2 levels also tend to decrease following BoNT‐A injections but this was not statistically significant compared to the preoperative levels.
Conclusion
This preliminary study, suggests urinary TGF‐Beta‐1 and NGF as a potent marker in children with NDOA, as they decline following BoNT‐A injection. Further studies are needed in identifying their special role in assessing treatment success after invasive interventions.</description><subject>Acetylcholine Release Inhibitors - therapeutic use</subject><subject>Biomarkers</subject><subject>botulinum neurotoxin type A</subject><subject>Botulinum toxin</subject><subject>Botulinum toxin type A</subject><subject>Botulinum Toxins, Type A - therapeutic use</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Female</subject><subject>Growth factors</subject><subject>Humans</subject><subject>Injections, Intramuscular</subject><subject>Male</subject><subject>Matrix metalloproteinase</subject><subject>Metalloproteinase</subject><subject>myelodysplasia</subject><subject>Myelodysplastic syndrome</subject><subject>Myelodysplastic syndromes</subject><subject>Nerve growth factor</subject><subject>Nerve Growth Factor - urine</subject><subject>Neural Tube Defects - complications</subject><subject>Prospective Studies</subject><subject>Statistical analysis</subject><subject>tissue inhibitor of matrix metalloproteinase 2</subject><subject>Tissue inhibitor of metalloproteinase 2</subject><subject>Tissue Inhibitor of Metalloproteinase-2 - urine</subject><subject>transforming growth factor beta 1</subject><subject>Transforming Growth Factor beta1 - urine</subject><subject>Transforming growth factor-b1</subject><subject>Treatment Outcome</subject><subject>Urinary Bladder, Neurogenic - drug therapy</subject><subject>Urinary Bladder, Neurogenic - etiology</subject><subject>Urinary Bladder, Neurogenic - urine</subject><subject>Urinary Bladder, Overactive - drug therapy</subject><subject>Urinary Bladder, Overactive - etiology</subject><subject>Urinary Bladder, Overactive - urine</subject><subject>Urine</subject><subject>Urodynamics</subject><issn>0733-2467</issn><issn>1520-6777</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc9u1DAQhy0EokvhwAsgS5yQSGs7Tpwcl6q7VCqFw_YcOfaEdZW1F__ZkhuPwIvwUjwJXlJ6Q5blGenzN9L8EHpNyRklhJ1bmc5YyYh4gha0YqSohRBP0YKIsiwYr8UJehHCHSGkKXn7HJ2whrSkrtoF-rXZAoZhABWxG7Cx0UsN0afgPO5dTKOxaYctJO-i-24sjtMe8BI7i5M3VvoJ36xX7_FmvcIfLjfL3z9-0txdffqSK4ZHOMAYsherrRm1B4vvTdzOwq9gjcKP49wBvFTRHEycsE6Ao8O7CUanp7AfZTDyJXo2yDHAq4f3FN2uLjcXH4vrz-uri-V1oY5bKCTltSK1alivZCvy6Xk_VKwSGjSveUV5o0HIVpectiTf_IHTQWlCa6pZeYrezt69d98ShNjdueRtHtnRtqSsaUVzpN7NlPIuBA9Dt_dmlzfSUdIdg-lyMN3fYDL75sGY-h3oR_JfEhk4n4F7M8L0f1N3s7ydlX8ARKeagg</recordid><startdate>201709</startdate><enddate>201709</enddate><creator>Top, Tuncay</creator><creator>Sekerci, Cagri Akin</creator><creator>Isbilen‐Basok, Banu</creator><creator>Tanidir, Yiloren</creator><creator>Tinay, Ilker</creator><creator>Isman, Ferruh Kemal</creator><creator>Akbal, Cem</creator><creator>Simsek, Ferruh</creator><creator>Tarcan, Tufan</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope></search><sort><creationdate>201709</creationdate><title>The effect of intradetrusor botulinum neurotoxin type A on urinary NGF, TGF BETA‐1, TIMP‐2 levels in children with neurogenic detrusor overactivity due to myelodysplasia</title><author>Top, Tuncay ; Sekerci, Cagri Akin ; Isbilen‐Basok, Banu ; Tanidir, Yiloren ; Tinay, Ilker ; Isman, Ferruh Kemal ; Akbal, Cem ; Simsek, Ferruh ; Tarcan, Tufan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3207-a146c06c82bca97979b4bf5257ded4645148de7a9d3419041914641fcd0161d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Acetylcholine Release Inhibitors - therapeutic use</topic><topic>Biomarkers</topic><topic>botulinum neurotoxin type A</topic><topic>Botulinum toxin</topic><topic>Botulinum toxin type A</topic><topic>Botulinum Toxins, Type A - therapeutic use</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Female</topic><topic>Growth factors</topic><topic>Humans</topic><topic>Injections, Intramuscular</topic><topic>Male</topic><topic>Matrix metalloproteinase</topic><topic>Metalloproteinase</topic><topic>myelodysplasia</topic><topic>Myelodysplastic syndrome</topic><topic>Myelodysplastic syndromes</topic><topic>Nerve growth factor</topic><topic>Nerve Growth Factor - urine</topic><topic>Neural Tube Defects - complications</topic><topic>Prospective Studies</topic><topic>Statistical analysis</topic><topic>tissue inhibitor of matrix metalloproteinase 2</topic><topic>Tissue inhibitor of metalloproteinase 2</topic><topic>Tissue Inhibitor of Metalloproteinase-2 - urine</topic><topic>transforming growth factor beta 1</topic><topic>Transforming Growth Factor beta1 - urine</topic><topic>Transforming growth factor-b1</topic><topic>Treatment Outcome</topic><topic>Urinary Bladder, Neurogenic - drug therapy</topic><topic>Urinary Bladder, Neurogenic - etiology</topic><topic>Urinary Bladder, Neurogenic - urine</topic><topic>Urinary Bladder, Overactive - drug therapy</topic><topic>Urinary Bladder, Overactive - etiology</topic><topic>Urinary Bladder, Overactive - urine</topic><topic>Urine</topic><topic>Urodynamics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Top, Tuncay</creatorcontrib><creatorcontrib>Sekerci, Cagri Akin</creatorcontrib><creatorcontrib>Isbilen‐Basok, Banu</creatorcontrib><creatorcontrib>Tanidir, Yiloren</creatorcontrib><creatorcontrib>Tinay, Ilker</creatorcontrib><creatorcontrib>Isman, Ferruh Kemal</creatorcontrib><creatorcontrib>Akbal, Cem</creatorcontrib><creatorcontrib>Simsek, Ferruh</creatorcontrib><creatorcontrib>Tarcan, Tufan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Neurourology and urodynamics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Top, Tuncay</au><au>Sekerci, Cagri Akin</au><au>Isbilen‐Basok, Banu</au><au>Tanidir, Yiloren</au><au>Tinay, Ilker</au><au>Isman, Ferruh Kemal</au><au>Akbal, Cem</au><au>Simsek, Ferruh</au><au>Tarcan, Tufan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of intradetrusor botulinum neurotoxin type A on urinary NGF, TGF BETA‐1, TIMP‐2 levels in children with neurogenic detrusor overactivity due to myelodysplasia</atitle><jtitle>Neurourology and urodynamics</jtitle><addtitle>Neurourol Urodyn</addtitle><date>2017-09</date><risdate>2017</risdate><volume>36</volume><issue>7</issue><spage>1896</spage><epage>1902</epage><pages>1896-1902</pages><issn>0733-2467</issn><eissn>1520-6777</eissn><abstract>Aims
The aim of this study was to determine the value of urine nerve growth factor (NGF), transforming growth factor beta 1 (TGF‐Beta‐1), tissue inhibitor of matrix metalloproteinase 2 (TIMP‐2) levels to predict the urodynamic profile before and after botulinum neurotoxin type A (BoNT‐A) treatment in children with myelodysplasia.
Methods
This prospective study included 15 children with myelodysplasia who underwent intradetrusor BoNT‐A injections due to neurogenic detrusor overactivity (NDOA). Urine samples of each child were collected before and after BoNT‐A injections, specifically at the first and third postoperative months. Urine samples were analyzed with ELISA method and NGF, TGF‐Beta‐1, and TIMP‐2 levels were measured. Urine marker levels and clinical findings were assessed for statistical significance with Wilcoxon Signed Ranks Test and Friedman Test.
Results
A total of 15 children (5 boys and 10 girls) were assigned as the study group. Mean age of the patients was 7.1 ± 2.5 years (range 2.5‐11). A statistically significantly decline was observed in urinary TGF‐Beta‐1 and NGF levels following BoNT‐A injections, compared to the preoperative levels (P < 0.05). TIMP‐2 levels also tend to decrease following BoNT‐A injections but this was not statistically significant compared to the preoperative levels.
Conclusion
This preliminary study, suggests urinary TGF‐Beta‐1 and NGF as a potent marker in children with NDOA, as they decline following BoNT‐A injection. Further studies are needed in identifying their special role in assessing treatment success after invasive interventions.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>28090659</pmid><doi>10.1002/nau.23207</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0733-2467 |
| ispartof | Neurourology and urodynamics, 2017-09, Vol.36 (7), p.1896-1902 |
| issn | 0733-2467 1520-6777 |
| language | eng |
| recordid | cdi_proquest_journals_1931289782 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Acetylcholine Release Inhibitors - therapeutic use Biomarkers botulinum neurotoxin type A Botulinum toxin Botulinum toxin type A Botulinum Toxins, Type A - therapeutic use Child Child, Preschool Children Enzyme-linked immunosorbent assay Female Growth factors Humans Injections, Intramuscular Male Matrix metalloproteinase Metalloproteinase myelodysplasia Myelodysplastic syndrome Myelodysplastic syndromes Nerve growth factor Nerve Growth Factor - urine Neural Tube Defects - complications Prospective Studies Statistical analysis tissue inhibitor of matrix metalloproteinase 2 Tissue inhibitor of metalloproteinase 2 Tissue Inhibitor of Metalloproteinase-2 - urine transforming growth factor beta 1 Transforming Growth Factor beta1 - urine Transforming growth factor-b1 Treatment Outcome Urinary Bladder, Neurogenic - drug therapy Urinary Bladder, Neurogenic - etiology Urinary Bladder, Neurogenic - urine Urinary Bladder, Overactive - drug therapy Urinary Bladder, Overactive - etiology Urinary Bladder, Overactive - urine Urine Urodynamics |
| title | The effect of intradetrusor botulinum neurotoxin type A on urinary NGF, TGF BETA‐1, TIMP‐2 levels in children with neurogenic detrusor overactivity due to myelodysplasia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T09%3A28%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20intradetrusor%20botulinum%20neurotoxin%20type%20A%20on%20urinary%20NGF,%20TGF%20BETA%E2%80%901,%20TIMP%E2%80%902%20levels%20in%20children%20with%20neurogenic%20detrusor%20overactivity%20due%20to%20myelodysplasia&rft.jtitle=Neurourology%20and%20urodynamics&rft.au=Top,%20Tuncay&rft.date=2017-09&rft.volume=36&rft.issue=7&rft.spage=1896&rft.epage=1902&rft.pages=1896-1902&rft.issn=0733-2467&rft.eissn=1520-6777&rft_id=info:doi/10.1002/nau.23207&rft_dat=%3Cproquest_cross%3E1931289782%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1931289782&rft_id=info:pmid/28090659&rfr_iscdi=true |